New safety information from post-market use of MabCampath has been reported and includes serious and sometimes fatal adverse reactions of haemophagocytic lymphohistiocytosis (HLH), stroke (including ischaemic and haemorrhagic stroke), and glomerulonephritis.
RecallTracker